Oncology & Cancer

ASCO names Cancer Advance of the Year

The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic ...

Oncology & Cancer

Two years of tamoxifen offers long-term survival benefit

(HealthDay)—For premenopausal women with breast cancer, two years of tamoxifen is associated with long-term survival benefit, according to a study published online May 9 in the Journal of Clinical Oncology.

Oncology & Cancer

Breast cancer treatments more effective now than in the past

(HealthDay)—Comparison of recurrence and outcome patterns shows that current treatments for breast cancer are more effective than previous therapies, according to research published online Nov. 24 in the Journal of Clinical ...

Oncology & Cancer

ADT plus radiotherapy ups survival in metastatic prostate CA

(HealthDay)—For men with metastatic prostate cancer (mPCa), overall survival (OS) is improved for those treated with androgen deprivation therapy (ADT) and prostate radiotherapy (RT), compared with ADT alone, according ...

Oncology & Cancer

Statins reduce risk of mortality in multiple myeloma

(HealthDay)—Statin therapy is associated with reduced risk of all-cause and multiple myeloma (MM)-specific mortality, according to a study published online Sept. 19 in the Journal of Clinical Oncology.

page 8 from 38